Patorno E, et al. - Researchers assessed the risk of hospitalization for heart failure (HHF) among type 2 diabetes (T2D) patients starting empagliflozin (a sodium-glucose co-transporter-2 inhibitor) vs sitagliptin (a dipeptidyl peptidase-4 inhibitor) in this first interim analysis from the EMPRISE study which assesses empagliflozin's effectiveness, safety, and healthcare use in routine care from August 2014 through September 2019. They created a 1:1 propensity-score (PS) matched cohort of T2D patients ≥18 years starting empagliflozin or sitagliptin using two commercial and one federal (Medicare) claims data sources in the US. Overall 16,443 patient pairs were identified after PS-matching. In routine care, patients with T2D (with and without a history of cardiovascular disease) who started empagliflozin vs sitagliptin had a decreased risk of HHF.